IGC Pharma annual depreciation and amortization
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Depreciation & Amortization Growth & History (IGC)
IGC Pharma's depreciation and amortization was $324,000 for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $324,000 | — | — |
| 2025 · Mar 31 | 2025-03-31 | $618,000 | −$19,000 | −2.98% |
| 2024 | 2024-03-31 | $637,000 | −$20,000 | −3.04% |
| 2023 | 2023-03-31 | $657,000 | $6,000 | +0.92% |
| 2022 | 2022-03-31 | $651,000 | $173,000 | +36.19% |
| 2021 | 2021-03-31 | $478,000 | $334,000 | +231.94% |
| 2020 | 2020-03-31 | $144,000 | $85,000 | +144.07% |
| 2019 | 2019-03-31 | $59,000 | $40,000 | +210.53% |
| 2018 | 2018-03-31 | $19,000 | −$377,346 | −95.21% |
| 2017 | 2017-03-31 | $396,346 | −$332,395 | −45.61% |
| 2016 | 2016-03-31 | $728,741 | −$52,805 | −6.76% |
| 2015 | 2015-03-31 | $781,546 | $69,232 | +9.72% |
| 2014 | 2014-03-31 | $712,314 | $38,398 | +5.70% |
| 2013 | 2013-03-31 | $673,916 | −$322,487 | −32.37% |
| 2012 | 2012-03-31 | $996,403 | $211,337 | +26.92% |
| 2011 | 2011-03-31 | $785,066 | — | — |
IGC Pharma quarterly depreciation and amortization
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | $56,000 | −$85,000 | −60.28% |
| Q1 2026 · Mar 31 | 2026-03-31 | $58,000 | −$96,000 | −62.34% |
| Q4 2025 | 2025-12-31 | $64,000 | −$93,000 | −59.24% |
| Q2 2026 · Sep 30 | 2025-09-30 | $119,000 | −$26,000 | −17.93% |
| Q1 2026 · Jun 30 | 2025-06-30 | $141,000 | −$21,000 | −12.96% |
| Q4 2025 | 2025-03-31 | $154,000 | — | — |
| Q3 2025 | 2024-12-31 | $157,000 | −$3,000 | −1.88% |
| Q2 2025 | 2024-09-30 | $145,000 | −$13,000 | −8.23% |
| Q1 2025 | 2024-06-30 | $162,000 | $7,000 | +4.52% |
| Q3 2024 | 2023-12-31 | $160,000 | −$12,000 | −6.98% |
| Q2 2024 | 2023-09-30 | $158,000 | −$12,000 | −7.06% |
| Q1 2024 | 2023-06-30 | $155,000 | −$7,000 | −4.32% |
| Q3 2023 | 2022-12-31 | $172,000 | $6,000 | +3.61% |
| Q2 2023 | 2022-09-30 | $170,000 | $7,000 | +4.29% |
| Q1 2023 | 2022-06-30 | $162,000 | $5,000 | +3.18% |
| Q3 2022 | 2021-12-31 | $166,000 | $39,000 | +30.71% |
| Q2 2022 | 2021-09-30 | $163,000 | $55,000 | +50.93% |
| Q1 2022 | 2021-06-30 | $157,000 | $80,000 | +103.90% |
| Q3 2021 | 2020-12-31 | $127,000 | $103,000 | +429.17% |
| Q2 2021 | 2020-09-30 | $108,000 | $80,000 | +285.71% |
| Q1 2021 | 2020-06-30 | $77,000 | $60,000 | +352.94% |
| Q3 2020 | 2019-12-31 | $24,000 | $10,000 | +71.43% |
| Q2 2020 | 2019-09-30 | $28,000 | $14,000 | +100.00% |
| Q1 2020 | 2019-06-30 | $17,000 | $2,000 | +13.33% |
| Q3 2019 | 2018-12-31 | $14,000 | $9,000 | +180.00% |
| Q2 2019 | 2018-09-30 | $14,000 | $10,000 | +250.00% |
| Q1 2019 | 2018-06-30 | $15,000 | $9,036 | +151.51% |
| Q3 2018 | 2017-12-31 | $5,000 | −$191,103 | −97.45% |
| Q2 2018 | 2017-09-30 | $4,000 | −$93,842 | −95.91% |
| Q1 2018 | 2017-06-30 | $5,964 | −$91,708 | −93.89% |
| Q3 2017 | 2016-12-31 | $196,103 | $53,103 | +37.13% |
| Q2 2017 | 2016-09-30 | $97,842 | −$51,013 | −34.27% |
| Q1 2017 | 2016-06-30 | $97,672 | −$58,302 | −37.38% |
| Q3 2016 | 2015-12-31 | $143,000 | −$10,725 | −6.98% |
| Q2 2016 | 2015-09-30 | $148,855 | −$6,299 | −4.06% |
| Q1 2016 | 2015-06-30 | $155,974 | $7,085 | +4.76% |
| Q3 2015 | 2014-12-31 | $153,725 | $6,017 | +4.07% |
| Q2 2015 | 2014-09-30 | $155,154 | $7,304 | +4.94% |
| Q1 2015 | 2014-06-30 | $148,889 | −$405 | −0.27% |
| Q3 2014 | 2013-12-31 | $147,708 | $12,924 | +9.59% |
| Q2 2014 | 2013-09-30 | $147,850 | −$97,275 | −39.68% |
| Q1 2014 | 2013-06-30 | $149,294 | $65,700 | +78.59% |
| Q3 2013 | 2012-12-31 | $134,784 | $92,424 | +218.19% |
| Q2 2013 | 2012-09-30 | $245,125 | $169,504 | +224.15% |
| Q1 2013 | 2012-06-30 | $83,594 | $32,350 | +63.13% |
| Q3 2012 | 2011-12-31 | $42,360 | −$419,268 | −90.82% |
| Q2 2012 | 2011-09-30 | $75,621 | −$25,309 | −25.08% |
| Q1 2012 | 2011-06-30 | $51,244 | −$45,200 | −46.87% |
| Q3 2011 | 2010-12-31 | $461,628 | — | — |
| Q2 2011 | 2010-09-30 | $100,930 | — | — |
| Q1 2011 | 2010-06-30 | $96,444 | — | — |
IGC Pharma depreciation and amortization trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's depreciation and amortization decreased from $785,066 to $324,000, a change of −$461,066. The latest reported quarter, Q2 2026 · Jun 30, shows $56,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗